廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,010.66
    +17.52 (+0.59%)
     
  • 滬深300

    3,520.96
    +18.18 (+0.52%)
     
  • 美元

    7.8256
    +0.0026 (+0.03%)
     
  • 人民幣

    0.9228
    -0.0004 (-0.04%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0514
    -0.0000 (-0.04%)
     
  • 歐元

    8.4404
    -0.0288 (-0.34%)
     
  • 英鎊

    9.8770
    -0.0080 (-0.08%)
     
  • 紐約期油

    83.11
    +1.76 (+2.16%)
     
  • 金價

    2,254.80
    +42.10 (+1.90%)
     
  • Bitcoin

    70,824.12
    +1,734.06 (+2.51%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst

  • PepGen Inc (NASDAQ: PEPG) reported data from PGN-EDO51's SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities.

  • SVB notes that PGN-EDO51's safety profile was generally well-tolerated. However, the 15mg/kg dose saw mild hypomagnesemia and an SAE of transient kidney biomarker changes, both events commonly linked to the peptide conjugates that aid oligo delivery.

  • It reiterates its Outperform rating with a price target of $6.

  • On the other hand, the analyst views the muscle concentration and exon skipping data from bicep muscle biopsies as highly encouraging and supportive of PGN-EDO51's best-in-class potential.

  • SVB says the mean exon skipping observed at 10mg/kg and 15mg/kg easily clears the bar set by Sarepta Therapeutics Inc (NASDAQ: SRPT) SRP-5051 healthy volunteers' exon skipping data of <0.2% at a higher 20mg/kg dose.

  • SRP-5051 easily beats the low bar set by Exondys 51, with mean exon skipping of ~11% and mean dystrophin expression of ~6.5% seen at the 30mg/kg dose in the Phase 2 MOMENTUM Part A results.

  • Sarepta's results suggest that SRP-5051 drove approx. 13x greater exon skipping in patients vs. what was seen in healthy volunteers.

  • Applying the same with PGN-EDO51, 10mg/kg could achieve ~18% exon skipping, and 15mg/kg could achieve ~26% exon skipping, using a rough analysis.

  • This would suggest that the 10-15mg/kg doses of PGN-EDO51 have the potential for enhanced exon skipping and dystrophin production capabilities relative to the 30mg/kg dose of SRP-5051.

  • Price Action: PEPG shares are up 77.40% at $9.23 on the last check Wednesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.